Therapeutic targeting of protein arginine methyltransferases reduces breast cancer progression by disrupting angiogenic pathways
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Protein arginine methylation is an epigenetic modification involved in transcription, splicing and signal transduction and is mediated by protein arginine methyltransferases (PRMTs). PRMTs regulate various tumor angiogenesis pathways, including vascular endothelial growth factor receptor-2 (VEGFR-2) signaling. PRMT1, PRMT4, and PRMT5 activate distinct stages of angiogenesis. For example, inhibiting PRMT5 suppresses VEGF-induced vessel sprouting in experimental models while impairing hypoxia-inducible factor 1-alpha (HIF-1α) stability and VEGFR-2 phosphorylation. PRMT1 and PRMT4 similarly influence VEGF isoform expression, leading to increased angiogenesis. Targeting PRMTs in experimental models results in suppressed angiogenesis and reduced cancer progression. Several small-molecule PRMT inhibitors, including GSK3326595 and EPZ015666, have entered early-phase clinical trials for solid tumors. These agents show promise in inhibiting tumor angiogenesis, although there are toxicity concerns. This review examines the mechanistic basis and therapeutic rationale for targeting PRMTs in breast cancer and discusses combination approaches to overcome resistance. We integrate preclinical and emerging clinical data to highlight the potential antiangiogenic and tumor-suppressive effects of PRMT inhibitors, providing insights for future therapeutic strategies for breast cancer.
HIGHLIGHTS
• Dysregulated arginine methylation may drive aberrant angiogenic signaling pathways in breast cancer.
• Arginine methylation controls endothelial cell functions via cytokines, growth factors, and related mediators.
• Inhibiting arginine methylation may help counteract dysregulated angiogenic signaling in breast cancer.
Description
DATA AVAILABILITY : No data was used for the research described in the article.
Keywords
Protein arginine methylation, Protein arginine methyltransferases (PRMTs), Breast cancer, Angiogenesis, Angiogenic signaling pathways, Hypoxia, Vascularization, Protein arginine methyltransferase inhibitors
Sustainable Development Goals
SDG-03: Good health and well-being
Citation
Maphalala, K., Ramali, D.P., Maebele, L.T. et al. 2025, 'Therapeutic targeting of protein arginine methyltransferases reduces breast cancer progression by disrupting angiogenic pathways', Biochemistry and Biophysics Reports, vol. 43, art. 102172, pp. 1-13, doi : 10.1016/j.bbrep.2025.102172.